Renal infarction is a rare condition with an incidence of 0.004–0.007% at presentation to an emergency department 1,2 and 1.4% at post mortem. 3 Diagnosis is often delayed, by an average of 4 ...

Acute renal infarction (ARI) is a rare disease that is often misdiagnosed initially because of its nonspecific presentation. In this Case Study, Nasser and colleagues describe a patient with ARI ...

At the time of renal scintigraphy, the frequency of acute kidney injury was higher in patients with renal infarction, and the likelihood of renal infarction diagnosis according to the presence or ...

Acute kidney injury in a context of cardiac amyloidosis may be due to renal infarction, report scientists in a new study published in Mayo Clinic Proceedings Rochester, MN, May 15, 2019 - Systemic ...

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

For patients with acute MI at increased risk for HF, empagliflozin showed cardiorenal benefits and was safe to initiate early ...

Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with acute myocardial infarction (MI), according to a study published ...

Total adverse events of heart failure or all-cause mortality were reduced with empagliflozin, regardless of kidney function.